September 22-23, 2009 | Boston, MA HIV Acute Infection Meeting

General InformationAgendaRegistrationAbstract SubmissionHotel & TravelDirections & ParkingDates to RememberFAQ & Contacts


Abstract Submission


ABSTRACT SUBMISSION IS NOW CLOSED. Late Breaker Dispositions will be emailed on Friday, August 28, 2009.

Late Breaker Abstract Submission will close August 24, 2009 at 9:00 a.m. Abstracts are limited to 2,500 characters (including spaces). All abstracts submitted will be printed electronically from submitted material. Please be sure to carefully check your abstract for errors associated with grammatical content, spelling, names, etc., before submitting.

Please follow the guidelines below for preparing your abstract. Abstracts that do not comply with the stated specifications may be returned for editing.

GENERAL GUIDELINES: ACUTE HIV WORKSHOP, SEPTEMBER 22–23, 2009

Abstracts should contain the following four components (please copy and paste your abstract into the abstract field based on the example below).

Abstract Example:

Background:
A concise statement of the issue under investigation or a hypothesis.

Methods:
The experimental methods used (including the statistical analyses employed).

Results:
Specific findings (please avoid promises such as "to be completed" or "to be presented").

Conclusions:
A summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; please avoid concluding statements such as "the results will be discussed").

Please do not include grant acknowledgements, literature references, or copyright or trademark symbols. Preference will be given to abstracts that report new information not previously published or presented at a national or international scientific meeting.  Please consider ways to incorporate data from the same study in one abstract rather than submitting multiple overlapping abstracts. Please do not submit abstracts unless the presenting author plans to attend the meeting and present their abstract as scheduled. 

REQUIRED ABSTRACT FORMAT

  • Subject Category:  For review and scheduling purposes, abstracts will be divided into categories.  Please read all of the categories before selecting the most appropriate one for your abstract.

  • Title:  Use a concise title that indicates the content of the abstract.  Capitalize the first letter of each word except prepositions, articles, and species names.  Specific names of microorganisms should be italicized.
     
  • Authors:  Authors' names should be typed in upper- and lowercase letters (please do not use all capital letters).  Use first name and last name.  The author presenting the paper must be designated.  There is a limit of 10 authors per abstract.
     
  • Affiliations:  If domestic, each author should be listed by institution, city, state, and country.  If international, each author should be listed by institution, city, and country. Do not include department, division, laboratory, etc.  Grant acknowledgements should not appear in abstracts.
     
  • Abstract Body:  Abstracts are limited to 2,500 characters (this includes spaces).
Please direct any questions regarding issues relevant to abstract submissions to:


Stayse Archibald

Conference Planner

Phone:

301-577-0244, ext. 43

Fax:

301-577-5261

E-mail:

sarchibald@blseamon.com

Web site:

www.blseamon.com


SCIENTIFIC ORGANIZING COMMITTEE

Dr. Todd Allen
Ragon Institute of MGH, MIT, and Harvard
Charlestown, MA

Dr. Marcus Altfeld
Massachusetts General Hospital
Harvard Medical School
Charlestown, MA

Dr. Myron S. Cohen
Associate Vice Chancellor
J. Herbert Bate Distinguished Professor
UNC Institute of Global Health & Infectious Disease
University of North Carolina at Chapel Hill
Chapel Hill, NC

Dr. Barton F. Haynes
Duke Human Vaccine Institute
Duke University Medical Center
Durham, NC

Dr. Frederick (Rick) Hecht
UCSF Positive Health Program
San Francisco General Hospital, Ward 84
San Francisco, CA

Dr. Eric Hunter
Professor of Pathology & Laboratory Medicine
Georgia Research Alliance Eminent Scholar
Emory Vaccine Center
Atlanta, GA

Dr. Susan Little
Antiviral Research Center
University of California, San Diego
San Diego, CA

Dr. James I. Mullins
Professor, Department of Microbiology
University of Washington
Seattle, WA

Dr. Douglas Nixon
UCSF Immunology Program
Division of Experimental Medicine
University of California, San Francisco
San Francisco, CA

Dr. Julie Overbaugh
Human Biology Division
Fred Hutchinson Cancer Research Center
Seattle, WA

Dr. Douglas D. Richman
Center for AIDS Research
University of California, San Diego
La Jolla, CA

Dr. Eric Rosenberg
Infectious Disease Unit
Massachusetts General Hospital
Boston, MA


National Institutes of Allergy and Infectious Diseases (NIAID) | National Institutes of Health DHHS | CFAR